A glioma diagnosis demands both speed and precision. It demands speed because higher-grade gliomas grow over weeks rather than months, and the quality of surgical resection is directly tied to how much functioning brain tissue surrounds the tumour when the surgeon operates. It demands precision because gliomas arise inside the brain's own tissue rather than from a distinct boundary, making the decision of what to remove and what to preserve one of the most technically and ethically demanding in all of medicine. For international patients seeking gliomas treatment in Kerala, Aster Medcity in Kochi offers a centre with the infrastructure and the specialist to meet both demands. Dr. Dilip Panikar, Senior Consultant in Neurosurgery at Aster Medcity Kochi, is one of Kerala's most experienced neuro-oncologists, with expertise spanning neuro-oncology, skull base surgery, complex neurovascular surgery, and functional neurosurgery.
This guide explains what glioma treatment involves, how Dr. Dilip Panikar approaches complex cases, and how international patients can plan their journey for gliomas treatment in Kerala.
Understanding Gliomas: What Makes Them Surgically and Oncologically Distinct
Gliomas arise from the glial cells that support and protect neurons. Unlike tumours that form a clear boundary with surrounding brain tissue, gliomas infiltrate — cancer cells extend beyond the visible tumour margin into adjacent brain that appears, under both the microscope and MRI, to be normal. This infiltrative biology defines why glioma treatment is so much more complex than simply "removing a brain tumour."
WHO Grading and What It Means for Treatment Urgency
The WHO 2021 classification grades gliomas from Grade 1 through Grade 4 based on cellular proliferation, molecular markers, and clinical behaviour:
-
Grade 1: Pilocytic astrocytomas and similar slow-growing tumours, often curable by complete surgical resection
-
Grade 2: Low-grade diffuse gliomas including IDH-mutant astrocytomas and oligodendrogliomas slow-growing but progressive, requiring surgery and often adjuvant treatment
-
Grade 3: Anaplastic astrocytomas and anaplastic oligodendrogliomas higher proliferation rate, requiring surgery followed by radiotherapy and chemotherapy
-
Grade 4: Glioblastoma (IDH-wildtype) and IDH-mutant astrocytoma Grade 4 the most aggressive primary brain tumours, requiring maximal safe resection followed by concurrent chemoradiotherapy (Stupp protocol)
The molecular profile, particularly IDH mutation status, MGMT promoter methylation, and 1p/19q codeletion, determines prognosis and guides adjuvant treatment selection. IDH-mutant gliomas generally have a more favourable prognosis than IDH-wildtype glioblastoma, and MGMT methylation predicts response to temozolomide chemotherapy. These tests should be performed on tumour tissue from every surgical specimen.
Why Extent of Resection Defines the Treatment Trajectory
From all the identified factors affecting the survival and overall outcome of patients with glioma, the extent of resection is the only one that can be altered the patient's age or the glioma's molecular signature cannot be influenced. This makes the neurosurgeon's skill and the surgical technology available the most directly modifiable prognostic variable in glioma care.
Gross total resection, when safely achievable, improves survival and the effectiveness of subsequent radiation and chemotherapy by reducing residual tumour volume that would otherwise require systemic treatment to control. For Grade 2 and Grade 3 gliomas, complete or near-complete resection may delay progression by years. For glioblastoma, even incomplete resection improves outcomes versus biopsy alone.
Dr. Dilip Panikar: His Approach to Complex Glioma Cases
Dr. Dilip Panikar is a Senior Consultant in Neurosurgery at Aster Medcity Kochi, with qualifications of MBBS, MS (General Surgery), and MCh (Neurosurgery). His areas of special interest include neuro-oncology and skull base surgery, complex neurovascular surgery, paediatric neurosurgery, functional neurosurgery including epilepsy surgery, and reconstructive surgery for craniofacial deformities.
Academic and Professional Background
Dr. Dilip Panikar has served as Professor and Head of Department of Neurosurgery at Amrita Institute of Medical Sciences, Kochi, and as Associate Professor of Neurosurgery at Sri Chitra Thirunaal Institute for Medical Sciences and Technology, Thiruvananthapuram — two of South India's most respected medical institutions. He has published more than 25 research articles in prominent Indian and international medical journals, reflecting active engagement with the published evidence base that informs his clinical practice.
He is a member of the Neurological Society of India, Skull Base Surgery Society of India, Stereotactic and Functional Neurosurgery Society of India, Indian Society for Paediatric Neurosurgery, and Neurovascular Society of India. These memberships reflect specialist engagement at the national level across the full scope of his subspecialty interests.
He has served as postgraduate teacher in neurosurgery and examiner to many universities across the country, and has been faculty at operative and laboratory dissection workshops demonstrating specialised neurosurgical techniques. This academic and training role signals a surgeon whose technical standards are visible to peers and validated through examination and teaching activity.
His Specific Approach to Neuro-Oncology
Dr. Dilip Panikar's neuro-oncology focus means that glioma surgery is not an occasional part of a general neurosurgical practice. His clinical work at Aster Medcity includes the full range of brain tumour presentations — gliomas at all grades, skull base tumours, metastatic lesions, and meningiomas — with the accompanying infrastructure of the Aster Medcity Centre of Excellence in Neurosciences supporting his cases.
He has authored multiple blogs on brain tumour awareness and treatment, including posts on warning signs of brain tumours, treatment options, life after brain tumour treatment, and the Head Start paediatric brain tumour initiative, reflecting a commitment to patient education alongside technical practice. His published blog on "Things to be Aware about Brain Tumor Treatment Options" directly addresses the complexity of treatment selection that glioma patients face.
The Glioma Treatment Pathway at Aster Medcity Kochi
Gliomas treatment in Kerala at Aster Medcity operates within a multidisciplinary neuro-oncology framework, not as an isolated surgical programme.
Pre-Operative Assessment
For international patients arriving for glioma surgery at Aster Medcity, the pre-operative assessment covers:
-
High-resolution 3T MRI with gadolinium contrast for tumour characterisation and surgical planning
-
Advanced MRI sequences including functional MRI (fMRI) mapping eloquent cortex and DTI tractography mapping critical white matter pathways for tumours near motor or language areas
-
Magnetic resonance spectroscopy to characterise tumour metabolism
-
If seizures have been a presenting symptom, EEG and epilepsy centre input through Aster Medcity's dedicated Epilepsy Centre, which Dr. Panikar is also associated with
-
Comprehensive blood work and anaesthesia review
-
Neuropsychological assessment for tumours in cognitive or language regions
Surgical Approaches for Gliomas
-
Standard craniotomy with neuronavigation: Neuronavigation integrates pre-operative MRI and fMRI data into a real-time surgical guidance system, providing the surgeon with intraoperative orientation relative to tumour boundaries and adjacent eloquent structures. It is used for most glioma resections.
-
Awake craniotomy for eloquent region gliomas: For gliomas in or near language, motor, or other critically functional brain regions, awake craniotomy allows real-time intraoperative cortical mapping while the patient is conscious, performing tasks that confirm functional boundaries during resection. Dr. Panikar's functional neurosurgery expertise, confirmed through his membership of the Stereotactic and Functional Neurosurgery Society of India, directly supports his capability in awake craniotomy procedures.
-
5-ALA fluorescence-guided surgery: 5-aminolevulinic acid causes glioma cells to fluoresce under blue-violet light, allowing the surgeon to visualise tumour boundaries with greater precision than white-light microscopy. 5-ALA is particularly valuable for Grade 4 glioblastoma resection.
-
Skull base approaches for inferiorly located gliomas: For tumours in or near the skull base that are poorly accessible through standard craniotomy, Dr. Panikar's skull base surgery subspecialty provides the technical repertoire to approach these locations safely.
Adjuvant Treatment After Surgery
Following surgery, the molecular profiling result from the tumour specimen guides the adjuvant treatment plan:
-
Grade 2 IDH-mutant glioma: Watch-and-wait for completely resected low-risk tumours; radiotherapy and PCV or temozolomide chemotherapy for high-risk patients (age above 40, incomplete resection)
-
Grade 3 anaplastic glioma: Radiotherapy with concurrent and adjuvant chemotherapy (temozolomide or PCV based on 1p/19q status)
-
Grade 4 glioblastoma (IDH-wildtype): Stupp protocol — temozolomide concurrent with radiotherapy, followed by maintenance temozolomide for six cycles. MGMT methylation predicts benefit from temozolomide. Tumour Treating Fields (TTFields) is an additional option for selected patients
Aster Medcity's Centre of Excellence in Neurosciences is supported by the Aster International Institute of Oncology, providing access to radiation oncology, medical oncology, and neuro-oncology follow-up within the same institutional campus.
Planning Your Medical Journey for Gliomas Treatment in Kerala
For international patients preparing to travel to Aster Medcity Kochi for glioma surgery with Dr. Panikar, a structured pre-travel preparation directly reduces the evaluation time in India and gets the patient to surgery faster.
What to Prepare Before Traveling
-
All existing brain MRI images in DICOM format (not just reports), including the most recent gadolinium-enhanced scan
-
Any prior biopsy or pathology reports including molecular marker results if already performed
-
Complete medical history including neurological symptom onset, current medications, and seizure history
-
Family contact details and an identified accompanying person for the full stay
Send these to Karetrip for pre-assessment review by the Aster Medcity neurosurgery team before the medical visa application is made. This pre-assessment allows Dr. Panikar's team to review the imaging, confirm the provisional diagnosis and tumour grade, and provide a surgical plan and cost estimate before travel is booked.
Realistic Stay Timeline for International Patients
-
Pre-operative assessment on arrival: 2 to 3 days, covering MRI review, fMRI where indicated, blood tests, anaesthesia clearance, and neurosurgical consultation with Dr. Panikar
-
Surgery: Day 3 to 5 after arrival
-
Hospital stay post-surgery: 5 to 7 days with neurological monitoring and early mobilisation
-
Post-operative MRI (within 72 hours of surgery): Confirms extent of resection and guides adjuvant planning
-
Discharge from hospital to recovery accommodation: Day 7 to 10
-
Total in-Kerala stay before long-haul travel: 14 to 21 days depending on case complexity and recovery
Cost Context
Glioma craniotomy in India costs between Rs. 2,00,000 and Rs. 5,00,000 (USD 2,400 to USD 6,000) for standard resection at leading neurosurgery centres, with complex cases involving awake craniotomy, 5-ALA fluorescence, or skull base approaches at the higher end. This represents 60 to 80 percent savings versus equivalent surgery in the USA or UK.
For guidance on what the surgical technologies used in glioma surgery involve and what outcomes they achieve, read: Why More International Patients Are Choosing India for Glioma Removal Surgery
How Karetrip Connects International Patients to Dr. Dilip Panikar
International patients planning gliomas treatment in Kerala begin the process by sending existing imaging and medical history to Karetrip, which coordinates the pre-assessment review with Dr. Dilip Panikar's team at Aster Medcity before any travel is booked. This ensures the surgical plan is confirmed, the cost estimate is in place, and the medical visa documentation reflects the actual treatment required — all before the patient leaves home.
From pre-travel imaging review, medical visa coordination, and accommodation near Aster Medcity's Kochi campus, through discharge planning for adjuvant treatment continuation and post-operative follow-up at home, Karetrip manages every element of the international patient journey for gliomas treatment in Kerala.
Chat with our Medical care assistant, RUA, for quick guidance and support and take the first step toward getting your case reviewed by Dr. Dilip Panikar and the Aster Medcity neuro-oncology team.
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. Glioma management requires urgent evaluation by a qualified neurosurgeon and neuro-oncologist. Consult a specialist before making any treatment decision.